Medicaid Coverage of and Spending on GLP-1s
This brief discusses the current landscape of Medicaid GLP-1 coverage and examines recent trends in Medicaid prescriptions and gross spending on GLP-1s.
The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This brief discusses the current landscape of Medicaid GLP-1 coverage and examines recent trends in Medicaid prescriptions and gross spending on GLP-1s.
President Trump announced a health care framework that leaves open key questions, including those about out-of-pocket costs, premiums, federal spending, and health coverage for people with pre-existing conditions.
While codifying most-favored-nation drug pricing could be helpful for bringing more transparency to these arrangements and guaranteeing that drug companies will deliver on what they’ve promised, policymakers would need substantially more information to turn these backroom voluntary deals into law.
By suggesting mifepristone poses a danger to women who use it, anti-abortion senators are likely to create more confusion that could further erode the public's confidence in the abortion pill despite its decades-long safety record.
© 2026 KFF